A Prospective Head-to-Head Assessment of Cell-Based, Molecular and Molecular-Imaging Modalities of Testing Minimal Residual Disease in MM


A Prospective Head-to-Head Assessment of Cell-Based, Molecular and Molecular-Imaging Modalities of Testing Minimal Residual Disease in MM
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Ola Landgren, MD, PhD (2/9/15)
Korde N et al. Minimal residual disease (MRD) testing in newly diagnosed multiple myeloma (MM) patients: A prospective head-to-head assessment of cell-based, molecular, and molecular-imaging modalities. Proc ASH 2014;Abstract 2105.

Dr Landgren is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center in New York, New York.